Steven Ades, M.D., M.Sc.
Professor of Medicine, Hematology and Oncology
Medical Director, University of Vermont Cancer Center Clinical Trials Office
Medical Oncologist, UVM Health Network
149 Beaumont Ave
Firestone Medical Research Building
Larner College of Medicine
Burlington, VT 05405
United States
- M.D., McGill University
- M.Sc., Epidemiology, McGill University
- B.Sc., Chemistry, McGill University
Department of Medicine, Division of Hematology and Medical Oncology
University of Vermont Cancer Center
University of Vermont Office of Clinical Trials
BIO
Dr. Steven Ades is a medical oncologist at the University of Vermont Medical Center, professor at Larner College of Medicine, and the Medical Director of the UVM Cancer Center Clinical Trials Office.
Dr. Ades' postdoctoral training
Research Fellow, Tufts University School of Medicine
Fellowship in Hematology and Oncology, Tufts University
Queen's University postgraduation education in internal medicine, Kingston General & Hotel Dieu Hospitals
Publications
Dr. Ades' publications on Google Scholar
Area(s) of expertise
Academic/Research Areas
My research focus is the intersection of thrombosis and cancer. I am the co-leader of a large cohort study of patients with advanced cancers who receive education, risk stratification and where applicable thromboprophylaxis at the UVMMC. Our team reports on multiple short and long term outcomes in this population as well as implementation research of this model in community oncology settings. I am also investigating the impact of a novel medical treatment for moderate to severe hot flashes in men receiving androgen deprivation therapy for prostate cancer.
These include clinical research around adjuvant treatment options for patients with esophageal and stomach cancers, supportive care for patients undergoing abdominal radiation therapy including novel combinations of antiemetics in this setting (AVERT trial: NCT00970905), and the protective impact of lipid lowering agents called statins on the risk of venous blood clots in patients with advanced cancer. I also participate in many national cooperative group trials covering the cancer sites listed above.
Publications
Higgins LM, Lester-Coll NH, Ades S, Barry MM, Borrazzo EC, Ganguly EK, Anker CJ.
'CROSS'-ing into the 'Real World': a retrospective cohort study of patients receiving
trimodality and bimodality therapy for esophageal cancer. J Gastrointest Oncol. 2023 Apr 29;14(2):480-493. PMID: 37201058
Ades S, Holmes CE. Implementing guidelines to prevent cancer associated thrombosis: how can we do better? Res Pract Thromb Haemost. 2023 Jan 10;7(1). PMID: 36852109
Stapleton RD, Ford DW, Sterba KR, Nadig NR, Ades S, Back AL, Carson SS, Cheung KL, Ely J, Kross EK, Macauley RC, Maguire JM, Marcy TW, McEntee JJ, Menon PR, Overstreet A, Ritchie CS, Wendlandt B, Ardren SS, Balassone M, Burns S, Choudhury S, Diehl S, McCown E, Nielsen EL, Paul SR, Rice C, Taylor KK, Engelberg RA. Evolution of Investigating Informed Assent Discussions about CPR in Seriously Ill Patients. J Pain Symptom Manage. 2022 Jun; 63(6):e621-e632. PMID: 35595375
Ades S, Pulluri B, Holmes C, Lal I, Kumar S, Littenberg B. Risk factors for venous
thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER-Medicare analysis. Cancer Medicine. 2022. 11(8): 1817-26
Anker CJ, Lester-Coll NH, Akselrod D, Cataldo PA, Ades S. The Potential for
Overtreatment with Total Neoadjuvant Therapy (TNT): Consider One Local Therapy
Instead. Clinical Colorectal Cancer. 2022
Anker CJ, Akselrod D, Ades S, Bianchi NA, Lester-Coll NH, Cataldo PA. Non-Operative
Management (NOM) of Rectal Cancer: Literature Review & Translating Evidence into
Practice. Current Colorectal Cancer Reports. 2021;17(1):23–41.
Ades S, Adrianzen Herrera D, Lahey T, Thomas AA, Jasra S, Barry M, Sprague J, Dittus, Plante TB, Kelly J, Kaufman PA, Khan F, Hammond CJ, Gernander K, Parsons P, Holmes C. Cancer Care in the Wake of a Cyberattack: How to Prepare and What to Expect. JCO Oncology Practice. 2021. Accepted on July 2, 2021 and published at ascopubs.org/journal/op on August 2, 2021: DOI https://doi.org/10. 1200/OP.21.00116
Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open, 2021;4(1):e2033787. doi:10.1001. PMID 2774904
Ng HK, Rogala BG, Ades S, Schwartz JR, Ashikaga T, Vacek P, Holmes CE. Prospective evaluation of drug-drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation. J Oncol Pharm Pract. 2020 Feb 11: 1078155220901569. doi: 10.1177/1078155220901569. PMID: 32046579
Douce DR, Holmes CE, Cushman M, MacLean C, Ades S, Zakai NA. Risk Factors for Cancer-Associated Venous Thromboembolism: the Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic (VTE-PAAC) Study. J Thromb Haemost. 2019 Aug 18. doi: 10.1111/jth.14614. PMID: 31423717
Yang MX, Coates RF, Ambaye A, Cortright V, Mitchell JM, Buskey AM, Zubarik R, Liu JG, Ades S, Barry MM. NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors. Biomark Res. 2018 Apr 18,6:15. doi: 10.1186/s40364-018-0129-8. eCollections 2018 PMID: 29713473
Farina NH, Zingiryan A, Vrolijk MA, Perrapato SD, Ades S, Stein GS, Lian JB, Landry CL. Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention. 2018 Sep; 233(9): 6408-6417. doi: 10.1002/jcp.26593. PMID: 29663383
Ades S, Douce D, Holmes CE, Cory S, Prior S, Butenas S, Callas P, Cushman M. Effect of rosuvastatin on risk markers for venous thromboembolism in cancer. J Thromb Haemost. 2018 Mar 25. doi: 10.1111/jth.14004. PMID: 29575637
L. E. Ferri*, S. Ades*, T. Alcindor, M.R. Chasen, V. Marcus, M. Hickeson, G. Artho, M. P. Thirlwell. Peri-Operative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: A Multi-Center Phase II Trial. Ann Oncol; 23, 1512-1517, 2011 Oct 29.
(*Co-primary authorship Ferri & Ades)
Ades S. Adjuvant therapy for colon cancer in the elderly. Oncology 23(2):162-7, 2009.
Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Roger M, Franco E (for the Biomarkers of Cervical Cancer Risk Study Team).Selected Class I and Class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 122(12):2820-6, 2008.
Ades S, Maxfield LF, Gould CJ, Jones GK, Levy SB. Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors, Int J Oncol 28(3): 747-53, 2006
Bio
Dr. Steven Ades is a medical oncologist at the University of Vermont Medical Center, professor at Larner College of Medicine, and the Medical Director of the UVM Cancer Center Clinical Trials Office.
Dr. Ades' postdoctoral training
Research Fellow, Tufts University School of Medicine
Fellowship in Hematology and Oncology, Tufts University
Queen's University postgraduation education in internal medicine, Kingston General & Hotel Dieu Hospitals
Publications
Areas of Expertise
Academic/Research Areas
My research focus is the intersection of thrombosis and cancer. I am the co-leader of a large cohort study of patients with advanced cancers who receive education, risk stratification and where applicable thromboprophylaxis at the UVMMC. Our team reports on multiple short and long term outcomes in this population as well as implementation research of this model in community oncology settings. I am also investigating the impact of a novel medical treatment for moderate to severe hot flashes in men receiving androgen deprivation therapy for prostate cancer.
These include clinical research around adjuvant treatment options for patients with esophageal and stomach cancers, supportive care for patients undergoing abdominal radiation therapy including novel combinations of antiemetics in this setting (AVERT trial: NCT00970905), and the protective impact of lipid lowering agents called statins on the risk of venous blood clots in patients with advanced cancer. I also participate in many national cooperative group trials covering the cancer sites listed above.
Publications
Higgins LM, Lester-Coll NH, Ades S, Barry MM, Borrazzo EC, Ganguly EK, Anker CJ.
'CROSS'-ing into the 'Real World': a retrospective cohort study of patients receiving
trimodality and bimodality therapy for esophageal cancer. J Gastrointest Oncol. 2023 Apr 29;14(2):480-493. PMID: 37201058
Ades S, Holmes CE. Implementing guidelines to prevent cancer associated thrombosis: how can we do better? Res Pract Thromb Haemost. 2023 Jan 10;7(1). PMID: 36852109
Stapleton RD, Ford DW, Sterba KR, Nadig NR, Ades S, Back AL, Carson SS, Cheung KL, Ely J, Kross EK, Macauley RC, Maguire JM, Marcy TW, McEntee JJ, Menon PR, Overstreet A, Ritchie CS, Wendlandt B, Ardren SS, Balassone M, Burns S, Choudhury S, Diehl S, McCown E, Nielsen EL, Paul SR, Rice C, Taylor KK, Engelberg RA. Evolution of Investigating Informed Assent Discussions about CPR in Seriously Ill Patients. J Pain Symptom Manage. 2022 Jun; 63(6):e621-e632. PMID: 35595375
Ades S, Pulluri B, Holmes C, Lal I, Kumar S, Littenberg B. Risk factors for venous
thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER-Medicare analysis. Cancer Medicine. 2022. 11(8): 1817-26
Anker CJ, Lester-Coll NH, Akselrod D, Cataldo PA, Ades S. The Potential for
Overtreatment with Total Neoadjuvant Therapy (TNT): Consider One Local Therapy
Instead. Clinical Colorectal Cancer. 2022
Anker CJ, Akselrod D, Ades S, Bianchi NA, Lester-Coll NH, Cataldo PA. Non-Operative
Management (NOM) of Rectal Cancer: Literature Review & Translating Evidence into
Practice. Current Colorectal Cancer Reports. 2021;17(1):23–41.
Ades S, Adrianzen Herrera D, Lahey T, Thomas AA, Jasra S, Barry M, Sprague J, Dittus, Plante TB, Kelly J, Kaufman PA, Khan F, Hammond CJ, Gernander K, Parsons P, Holmes C. Cancer Care in the Wake of a Cyberattack: How to Prepare and What to Expect. JCO Oncology Practice. 2021. Accepted on July 2, 2021 and published at ascopubs.org/journal/op on August 2, 2021: DOI https://doi.org/10. 1200/OP.21.00116
Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open, 2021;4(1):e2033787. doi:10.1001. PMID 2774904
Ng HK, Rogala BG, Ades S, Schwartz JR, Ashikaga T, Vacek P, Holmes CE. Prospective evaluation of drug-drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation. J Oncol Pharm Pract. 2020 Feb 11: 1078155220901569. doi: 10.1177/1078155220901569. PMID: 32046579
Douce DR, Holmes CE, Cushman M, MacLean C, Ades S, Zakai NA. Risk Factors for Cancer-Associated Venous Thromboembolism: the Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic (VTE-PAAC) Study. J Thromb Haemost. 2019 Aug 18. doi: 10.1111/jth.14614. PMID: 31423717
Yang MX, Coates RF, Ambaye A, Cortright V, Mitchell JM, Buskey AM, Zubarik R, Liu JG, Ades S, Barry MM. NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors. Biomark Res. 2018 Apr 18,6:15. doi: 10.1186/s40364-018-0129-8. eCollections 2018 PMID: 29713473
Farina NH, Zingiryan A, Vrolijk MA, Perrapato SD, Ades S, Stein GS, Lian JB, Landry CL. Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention. 2018 Sep; 233(9): 6408-6417. doi: 10.1002/jcp.26593. PMID: 29663383
Ades S, Douce D, Holmes CE, Cory S, Prior S, Butenas S, Callas P, Cushman M. Effect of rosuvastatin on risk markers for venous thromboembolism in cancer. J Thromb Haemost. 2018 Mar 25. doi: 10.1111/jth.14004. PMID: 29575637
L. E. Ferri*, S. Ades*, T. Alcindor, M.R. Chasen, V. Marcus, M. Hickeson, G. Artho, M. P. Thirlwell. Peri-Operative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: A Multi-Center Phase II Trial. Ann Oncol; 23, 1512-1517, 2011 Oct 29.
(*Co-primary authorship Ferri & Ades)
Ades S. Adjuvant therapy for colon cancer in the elderly. Oncology 23(2):162-7, 2009.
Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Roger M, Franco E (for the Biomarkers of Cervical Cancer Risk Study Team).Selected Class I and Class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 122(12):2820-6, 2008.
Ades S, Maxfield LF, Gould CJ, Jones GK, Levy SB. Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors, Int J Oncol 28(3): 747-53, 2006